Development of X-ray fluorescence technique for the uranium determination in Mongolian coal, coal ash, and phosphate ore

The results of the determination of uranium in Mongolian brown coal, coal ash, phosphate rock, and technological samples by X-ray fluorescence (XRF) spectrometry are presented. Technological samples were produced from phosphates by chemical treatment. Powder geological samples and Certified Reference Materials (CRMs) were pressed as tablets. For chosen conditions of the sample preparation procedure analytical figures of merit were carefully studied, as exemplified by the rock and uranium ore Reference Materials. The variance of the total uncertainty is 2 % for uranium in the analyzed samples, and one is 7 % in the rock CRMs. The estimated values of the uranium detection limit for the CRMs are within the interval from 1 to 3 ppm. For the correction of the matrix effects the background standard method was used. Values of the uranium contents in the studied samples vary within the interval from 3.0 to 35.0 ppm. The comparison of the wavelength dispersive (WD) XRF results with the energy dispersive (ED) XRF results and the neutron activation analysis (NAA) was performed. It is demonstrated that the WDXRF have satisfactorily agreed with the EDXRF results and the NAA within the limits of the uncertainty. It is shown that the values of the relative discrepancies between the WDXRF and EDXRF results are in the range of 2.0-18.0 %, and between the WDXRF and the NAA results are in the range of 2.0-20.0 %. These values are less than 30 %, yielding the third category of the precision of the mineral raw material analysis

Hypothermic organ perfusion in the 2020s: mixing the benefits of low temperatures and dynamic flow outside the body

The cold chain supply of donor organs for transplantation has been an integral part of the delivery of transplant clinical services over the past five decades. Within the technologies used for this, hypothermic machine perfusion (HMP) was a concept, which was attractive to maintain organs under optimal conditions outside the body, and many early research studies on HMP were reported. However, it took the arrival of important new concepts to ensure that HMP was logistically feasible and valuable from an organ physiology perspective within the clinical pathways. This review provides details of the current status of HMP across the range of organs transplanted in the clinic, and discusses what new areas might benefit from applying HMP in coming years. In conclusion, HMP is now being used more frequently for clinical organ preservation in a variety of settings. As new therapies such as cell or gene therapy become more common, HMP will continue to play an important facilitator role for optimising organs in the donor pathway

Удосконалення швидкісно-силових якостей боксерів 16–17 років

The paper deals with improving the speed and power as a boxer 16–17. An experimental technique that allows for a personalized and differentiated approach to the training process. Analyze the impact of the developed technique on the physical and functional condition of the boxers. The study showed that the technique has a positive impact on the development and improvement of the speed and power characteristics.Рассмотрены вопросы совершенствования скоростно-силовых качеств боксеров 16–17 лет. Предложена экспериментальная методика, которая позволяет реализовать индивидуальный и дифференцированный подход в тренировочном процессе. Проанализировано влияние разработанной методики на физическое и функциональное состояние боксеров. Исследование показало, что методика имеет положительное влияние на развитие и совершенствование скоростно-силовых качеств.Розглянуті питання удосконалення швидкісно-силових якостей боксерів 16–17 років. Запропоновано експериментальну методику, яка дозволяє реалізувати індивідуальний і диференційований підхід у тренувальному процесі. Проаналізовано вплив розробленої методики на фізичний і функціональний стан боксерів. Дослідження показало, що методика має позитивний вплив на розвиток і удосконалення швидкісно-силових якостей

Transport of neutrons and γ quanta through a highly filled polymer composite

The transport of neutrons and γ quanta of various energies through a polymer composite based on tungsten-filled track membranes is studie

Effect of electron irradiation on polyimide composites based on track membranes for space systems

The paper presents data on the resistance to electron irradiation of polyimide (PI) composite with nano-sized lead fille

DYNAMICS OF MORBIDITY OF POPULATION IN IRKUTSK BETWEEN DURING SOCIO-ECONOMIC REFORMS

This article presents an analysis of disease trends in selected age groups of the population of Irkutsk for the period of 1992-2009 and it is found that most of these trends are dependent on socio-economic factors. Built polynomial regression models revealed significant increase in morbidity of mental disorders in children, diseases of the nervous system and. the digestive system against opposing change prevalence of adolescent and. adult population for the analyzed period

Production of Bst polymerase for diagnosis of different infections using loop-mediated isothermal amplification

Introduction. The large fragment of DNA polymerase I from Geobacillus stearothermophilus GIM1.543 (Bst DNA polymerase) possesses 5'-3' DNA polymerase activity, 5'-3' displacement activity and high processivity. These properties make it possible to use Bst DNA polymerase in loop-mediated isothermal amplification (LAMP), which provides highly specific amplification of the target sequence and is used for rapid detection of agents causing human infectious diseases. The purpose of the study was to produce a recombinant Bst polymerase enzyme in the bacterial expression system and to assess its properties for LAMP-based diagnostics of infectious diseases. Materials and methods. Expression constructs carrying the Bst polymerase gene were obtained using genetic engineering techniques. Different Escherichia coli strains were used for protein expression. Metal-chelate and gel filtration chromatography techniques were used for protein purification. Catalytic characteristics of the enzyme were assessed in loop-mediated isothermal amplification reactions using AmpliSens SARS-CoV-2-IT, AmpliSens IAV-IT and AmpliSens IBV-IT diagnostic systems designed for high-quality detection of SARS-CoV-2, influenza A virus (IAV) and influenza B virus (IBV) RNA, respectively. Results. The offered protocol for production, extraction and purification of recombinant Bst polymerase makes it possible to produce the enzyme in the bacterial expression system using E. coli cells in a soluble form and reaching the yield up to 20% of the total cell mass. In LAMP reactions, the obtained enzyme demonstrates activity comparable with that of the commercial enzyme Bst 2.0 (NEB). Conclusion. Considering the fast purification and production of the enzyme, the obtained recombinant Bst polymerase can be used in LAMP-based diagnostic kits

ТРОМБОЛИТИЧЕСКАЯ И АНТИКОАГУЛЯНТНАЯ ТЕРАПИЯ ПРИ ТРОМБОЭМБОЛИИ ЛЕГОЧНОЙ АРТЕРИИ С ВЫСОКИМ И ПРОМЕЖУТОЧНЫМ РИСКОМ РАННЕЙ СМЕРТИ. ЧАСТЬ 1. ЛЕТАЛЬНОСТЬ И ОСЛОЖНЕНИЯ

Background The advantages of thrombolytic therapy over anticoagulant therapy in the treatment of acute pulmonary embolism are uncertain. Aim of study To compare primary outcomes and incidence of complications in patients with PE of high and intermediate risk in the course of TLT or ACT and to assess efficacy and safety of TLT and ACT. Study Design Prospective non-randomized study. Intervention was administration of a thrombolytic, the control group consisted of patients who had an anticoagulant introduced. Characteristics of a sample 503 patients with a high and intermediate risk of early death at the age of 16 to 93 years (mean age 61±16, Ме 63 (51; 74) admitted to the resuscitation department in 2011–2016. Thrombolytics were administered to 222 patients, heparin — 281. Results The mortality rate was 10.8% (24/222) when treated with thrombolytic vs. 17.8% (50/281) with anticoagulant treatment; odds ratio was 0.56, 95% confidence interval 0.32; 0.97; p=0.031; P=0.60. The mortality rate in the subgroup with unstable hemodynamics was 30.2% (19/63) with thrombolytics vs. 47.1% (32/68) with anticoagulant treatment; OR 0.49 (0.22; 1.06); p=0.051; P=0.51. The mortality rate in the subgroup of intermediate risk was 3.2% (5/158) vs. 8.4% (18/214); OR 0.36 (0.11; 1.05); p=0.049; P=0.54. The use of thrombolytic was associated with a decrease in mortality: in the age group< 75 (mortality rate 5.5% (10/181) vs. 16.2% (33/204), OR 0.30 (0.14; 0.67); p=0.001, P=0.92); in the subgroup with acute cardiac arrhythmias (mortality rate 4.5% (1/122) vs. 44.0% (11/25); OR 0.061 (0.003; 0.557); p=0.002; P=0.91); in the subgroup with no hospital recurrence of embolism (mortality rate 1.6% (3/188) vs. 12.9% (32/248); OR 0.14 (0.03; 0.46), p< 0.001; P=1.0). With thrombolysis, infarction pneumonia developed less often: in 19.8% (44/222) vs. 28.8% (81/281); OR 0.61 (0.39; 0.95); p=0.022; P=0.64. There were no differences in the incidence of hemorrhagic complications in the treatment of thrombolytics in comparison with anticoagulant therapy: 7.7% (17/222) vs. 10.3% (29/281); OR 0.72 (0.37; 1.40); p=0.35; P=0.17. Severe hemorrhages (including intracranial): 2.7% (6/22) vs. 3.2% (9/281); OR 0.84 (0.26; 2.62); p=0.80; P=0.06. Minor hemorrhages: 5.0% (11/ 222) vs. 7.1% (20/281); OR 0.72 (0.31; 1.63); p=0.36; P=0.16. Intracranial hemorrhages: 0.90% (2/222) vs. 0.71% (2/281); OR 1.27 (0.13; 12.67); p=0.81; P=0.13). There was no difference in the re-occurrence of embolisms: 15.3% (34/222) and 11.7% (33/281); OR 1.36 (0.79; 2.35); p=0.29; P=0.22. Conclusion Thrombolytic therapy appeared to be more effective for survival compared to anticoagulant therapy with no differences in the incidence of complications.АКТУАЛЬНОСТЬ Преимущества тромболитической терапии перед антикоагулянтной в лечении острой легочной эмболии неопределенны.Цель исследования Провести сравнительный анализ первичных исходов — летальности и частоты развития осложнений у пациентов с тромбоэмболией легочной артерии высокого и промежуточного риска при проведении тромболитической (ТЛТ) или антикоагулянтной терапии (АКТ). Оценить эффективность и безопасность ТЛТ и АКТ.Дизайн исследования Проспективное нерандомизированное исследование. Вмешательством являлось введение тромболитика, группой контроля — пациенты, которым вводился антикоагулянт.Характеристика выборки 503 пациентов высокого и промежуточного риска ранней смерти в возрасте от 16 до 93 лет (средний возраст 61±16, Ме 63 (51; 74) лет), поступивших в реанимационное отделение в 2011–2016 гг; 290 женщин, 213мужчин; тромболитик вводился 222 больным, гепарин — 281.Результаты Летальность при лечении тромболитиком 10,8% (24/222) против 17,8% (50/281) при лечении антикоагулянтом; отношение шансов 0,56, 95% доверительный интервал 0,32; 0,97; р=0,031; мощность (P) 0,60. Летальность в подгруппе с нестабильной гемодинамикой при введении тромболитика 30,2% (19/63) против 47,1% (32/68) при введении антикоагулянта; отношение шансов (ОШ) 0,49 (0,22; 1,06); р=0,051; Р=0,51. Летальность в подгруппе промежуточного риска 3,1% (5/159) против 8,5% (18/213); ОШ 0,35 (0,11; 1,04); р=0,048; Р=0,58. Использование тромболитика было ассоциировано со снижением летальности: в возрастной подгруппе< 75 лет (летальность 5,5% (10/181) против 16,2% (33/204); ОШ 0,30 (0,14; 0,67); р=0,001; Р=0,92); в подгруппе с острыми нарушениями сердечного ритма (летальность 4,5% (1/22) против 44,0% (11/25); ОШ 0,061 (0,003; 0,557), р=0,002; Р=0,91); в подгруппе с отсутствием госпитального рецидива эмболии (летальность 1,6% (3/188) против 12,9% (32/248); ОШ 0,14 (0,03; 0,46); р<0,001; Р=1,0). При тромболизисе реже развивалась инфарктная пневмония: в 19,8% (44/222) против 28,8% (81/281); ОШ 0,61(0,39; 0,95); р=0,022; Р=0,64. Не было выявлено различий в частоте геморрагических осложнений при лечении тромболитиком по сравнению с антикоагулянтом: 7,7% (17/222) против 10,3% (29/281); ОШ 0,72 (0,37; 1,40); р=0,35; Р=0,17. Тяжелые кровотечения (включая интракраниальные): 2,7% (6/22) против 3,2% (9/281); ОШ 0,84 (0,26; 2,62); р=0,80; Р=0,06. Незначительные кровотечения: 5,0% (11/222) против 7,1% (20/281); ОШ 0,72 (0,31; 1,63); р=0,36; Р=0,16. Интракраниальные кро- вотечения: 0,90% (2/222) против 0,71% (2/281); ОШ 1,27 (0,13; 12,67); р=0,81; Р=0,13). Не раз- личалась и частота повторных эмболий: 15,3% (34/222) и 11,7% (33/281); ОШ 1,36 (0,79; 2,35); р=0,29; Р=0,22. Заключение Тромболитическая терапия по сравнению с антикоагулянтной была эффективней для выживания; при этом статистически значимых различий в частоте развития осложнений не было выявлено. Ключевые слова: легочная эмболия, тромболитическая терапия, антикоагулянтная терапия, промежуточный риск неблагоприятного исхода, летальность, интракраниальные кровотечения, нарушения сердечного ритма>< 0,001; Р=1,0). При тромболизисе реже развивалась инфарктная пневмония: в 19,8% (44/222) против 28,8% (81/281); ОШ 0,61(0,39; 0,95); р=0,022; Р=0,64. Не было выявлено различий в частоте геморрагических осложнений при лечении тромболитиком по сравнению с антикоагулянтом: 7,7% (17/222) против 10,3% (29/281); ОШ 0,72 (0,37; 1,40); р=0,35; Р=0,17. Тяжелые кровотечения (включая интракраниальные): 2,7% (6/22) против 3,2% (9/281); ОШ 0,84 (0,26; 2,62); р=0,80; Р=0,06. Незначительные кровотечения: 5,0% (11/222) против 7,1% (20/281); ОШ 0,72 (0,31; 1,63); р=0,36; Р=0,16. Интракраниальные кровотечения: 0,90% (2/222) против 0,71% (2/281); ОШ 1,27 (0,13; 12,67); р=0,81; Р=0,13). Не различалась и частота повторных эмболий: 15,3% (34/222) и 11,7% (33/281); ОШ 1,36 (0,79; 2,35); р=0,29; Р=0,22.Заключение Тромболитическая терапия по сравнению с антикоагулянтной была эффективней для выживания; при этом статистически значимых различий в частоте развития осложнений не было выявлено

Deep refinement of tellurium: equipment and process improvement through process simulation

Simulation data have been presented on a process of deep refinement of tellurium based on Authors-developed refinement technique implemented through analysis of the process unit thermodynamical condition using Flow Simulation software, from SolidWorks software product. The technique put forward herein has been implemented in a plant comprising a vertical air-tight reaction chamber arranged inside a multi-zone thermal unit and executing a sequence of refinement stages which use different techniques and are integrated in a single process. The experimental data which have been the basis for calculations have allowed one to determine the boundary conditions of the mathematical model taking into account previous operation experience of the software product used. Temperature profile calculation has been carried out taking into account all the types of heat transfer in the system, the weight / dimensions parameters of system units and the physicochemical properties of refined tellurium, materials of equipment fittings and reactor media. The temperature modes of the process stages have been accepted as the boundary conditions for the thermal calculations, with temperatures being measured at equipment fitting locations at which temperature gages connected with a PID controller have been installed. The simulation of specific refinement process conditions allowed process modes and equipment fitting component design to be corrected. We have developed and produced test models of process and imitation equipment. Analysis of the thermal fields for the final model has shown good agreement with the mathematical model. Equipment upgrading and process parameter improvement on the basis of the simulation results have allowed T-u Grade tellurium (99.95 wt.%) refinement to a 99.99992 wt.% purity by 30 main impurities in the course of physical experiments, the product yield being at least 60%